CCWM
ALNY icon

Cassaday & Co Wealth Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Cassaday & Co Wealth Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$302 Sell
1
-4
-80% -$1.21K ﹤0.01% 1178
2026
Q1 		$1.66K Buy
+5
New +$1.7K ﹤0.01% 1088

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Cassaday & Co Wealth Management's ALNY Position: Q2 2026 in Review

Cassaday & Co Wealth Management reduced its Alnylam Pharmaceuticals (ALNY) stake by 80% in Q2 2026, selling an estimated $1.21K and leaving 1 share worth $302. The position accounts for ﹤0.01% of the portfolio, ranked #1178.

Cassaday & Co Wealth Management first reported a position in ALNY in Q1 2026 and has held it in 2 quarters since. The position peaked at $1.66K in Q1 2026. 790 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Cassaday & Co Wealth Management held 1 share of Alnylam Pharmaceuticals worth $302 as of Q2 2026.
  • Cassaday & Co Wealth Management sold 4 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $1.21K.
  • Alnylam Pharmaceuticals made up ﹤0.01% of Cassaday & Co Wealth Management's portfolio in Q2 2026, its #1178 holding.
  • Cassaday & Co Wealth Management first reported a position in Alnylam Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • Cassaday & Co Wealth Management's Alnylam Pharmaceuticals position peaked at $1.66K in Q1 2026.
  • 790 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Cassaday & Co Wealth Management's 13F filing for Q2 2026, filed 10 Aug 2026.